Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: A randomized, controlled trial

Samir Gupta, Deming Mi, Sharon Moe, Michael P. Dubé, Ziyue Liu

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

We performed a randomized controlled trial in 30 HIV-infected participants to either continue tenofovir/emtricitabine/efavirenz (Continuation Group) or switch to tenofovir/emtricitabine/raltegravir (Switch Group) for 24 weeks. There were no significant differences in the changes in flow-mediated dilation, 25(OH) vitamin D, or parathyroid hormone levels. Total cholesterol, high sensitivity C-reactive protein, serum alkaline phosphatase, sCD14 levels, and renal function significantly declined in the Switch Group compared with the Continuation Group; however, sCD163 levels significantly increased in the Switch Group. These findings suggest that raltegravir is not inherently more beneficial to endothelial function compared with efavirenz but may impact renal function and monocyte activation.

Original languageEnglish
Pages (from-to)279-283
Number of pages5
JournalJournal of Acquired Immune Deficiency Syndromes
Volume64
Issue number3
DOIs
StatePublished - Nov 1 2013

Fingerprint

Tenofovir
efavirenz
Minerals
Randomized Controlled Trials
Inflammation
Kidney
Bone and Bones
Parathyroid Hormone
Vitamin D
C-Reactive Protein
Alkaline Phosphatase
Dilatation
Monocytes
Cholesterol
HIV
Serum
Raltegravir Potassium
Emtricitabine

Keywords

  • efavirenz
  • endothelial function
  • monocyte activation
  • raltegravir
  • renal function
  • vitamin D

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)
  • Medicine(all)

Cite this

@article{44e49bee34d84eb1a682a5ea345a195a,
title = "Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: A randomized, controlled trial",
abstract = "We performed a randomized controlled trial in 30 HIV-infected participants to either continue tenofovir/emtricitabine/efavirenz (Continuation Group) or switch to tenofovir/emtricitabine/raltegravir (Switch Group) for 24 weeks. There were no significant differences in the changes in flow-mediated dilation, 25(OH) vitamin D, or parathyroid hormone levels. Total cholesterol, high sensitivity C-reactive protein, serum alkaline phosphatase, sCD14 levels, and renal function significantly declined in the Switch Group compared with the Continuation Group; however, sCD163 levels significantly increased in the Switch Group. These findings suggest that raltegravir is not inherently more beneficial to endothelial function compared with efavirenz but may impact renal function and monocyte activation.",
keywords = "efavirenz, endothelial function, monocyte activation, raltegravir, renal function, vitamin D",
author = "Samir Gupta and Deming Mi and Sharon Moe and Dub{\'e}, {Michael P.} and Ziyue Liu",
year = "2013",
month = "11",
day = "1",
doi = "10.1097/QAI.0b013e3182a97c39",
language = "English",
volume = "64",
pages = "279--283",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function

T2 - A randomized, controlled trial

AU - Gupta, Samir

AU - Mi, Deming

AU - Moe, Sharon

AU - Dubé, Michael P.

AU - Liu, Ziyue

PY - 2013/11/1

Y1 - 2013/11/1

N2 - We performed a randomized controlled trial in 30 HIV-infected participants to either continue tenofovir/emtricitabine/efavirenz (Continuation Group) or switch to tenofovir/emtricitabine/raltegravir (Switch Group) for 24 weeks. There were no significant differences in the changes in flow-mediated dilation, 25(OH) vitamin D, or parathyroid hormone levels. Total cholesterol, high sensitivity C-reactive protein, serum alkaline phosphatase, sCD14 levels, and renal function significantly declined in the Switch Group compared with the Continuation Group; however, sCD163 levels significantly increased in the Switch Group. These findings suggest that raltegravir is not inherently more beneficial to endothelial function compared with efavirenz but may impact renal function and monocyte activation.

AB - We performed a randomized controlled trial in 30 HIV-infected participants to either continue tenofovir/emtricitabine/efavirenz (Continuation Group) or switch to tenofovir/emtricitabine/raltegravir (Switch Group) for 24 weeks. There were no significant differences in the changes in flow-mediated dilation, 25(OH) vitamin D, or parathyroid hormone levels. Total cholesterol, high sensitivity C-reactive protein, serum alkaline phosphatase, sCD14 levels, and renal function significantly declined in the Switch Group compared with the Continuation Group; however, sCD163 levels significantly increased in the Switch Group. These findings suggest that raltegravir is not inherently more beneficial to endothelial function compared with efavirenz but may impact renal function and monocyte activation.

KW - efavirenz

KW - endothelial function

KW - monocyte activation

KW - raltegravir

KW - renal function

KW - vitamin D

UR - http://www.scopus.com/inward/record.url?scp=84886387920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886387920&partnerID=8YFLogxK

U2 - 10.1097/QAI.0b013e3182a97c39

DO - 10.1097/QAI.0b013e3182a97c39

M3 - Article

C2 - 24278992

AN - SCOPUS:84886387920

VL - 64

SP - 279

EP - 283

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 3

ER -